The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical-stage AI-enabled therapeutic assets: An industry-wide analysis of scale, clinical progression, and company characteristics.
 
Waqas Haque
No Relationships to Disclose
 
Kareena Sai-Palm
No Relationships to Disclose
 
Misa Kasparcova
No Relationships to Disclose
 
Iemaan Rana
No Relationships to Disclose
 
Loic Verlingue
Leadership - Resolved
Consulting or Advisory Role - Adaptherapy
Research Funding - Bristol-Myers Squibb
 
Marina Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; IO Biotech; Janssen; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Novocure; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Pietro Veronesi
No Relationships to Disclose